In conclusion, the data presented in this study argue for the protective potential of microenvironmentally mediated activation of the alternative NFκB pathway in MCL cells against BCR signaling-associated drugs, which might represent a physiologic niche for MCL relapse. Here, BCR is linked to mantle cell lymphoma.